Adaptive clinical trials in oncology
暂无分享,去创建一个
[1] Donald A. Berry,et al. Statistics: A Bayesian Perspective , 1995 .
[2] Number of cancer drugs in development rises in the USA , 2001 .
[3] D. Harrington. Group Sequential Methods with Applications to Clinical Trials. Christopher Jennison and Bruce W. Turnbull, CRC/Chapman & Hall, U.K., 2000. No. of pages: xviii +390. Price: £ 39.00. ISBN 0‐849‐30316‐8 , 2001 .
[4] Meir Glick,et al. Pattern recognition and massively distributed computing , 2002, J. Comput. Chem..
[5] Peter F Thall,et al. Dose‐Finding with Two Agents in Phase I Oncology Trials , 2003, Biometrics.
[6] Donald A Berry,et al. Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis , 2005, Clinical trials.
[7] D. Berry. Bayesian clinical trials , 2006, Nature Reviews Drug Discovery.
[8] Xuelin Huang,et al. A Parallel Phase I/II Clinical Trial Design for Combination Therapies , 2007, Biometrics.
[9] D. Sargent,et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Lilford,et al. The relationship between progression-free and post-progression survival in treating four types of metastatic cancer. , 2008, Cancer letters.
[11] M. Buyse,et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Buyse,et al. Prediction of survival benefits from progression-free survival in patients with advanced non small cell lung cancer: Evidence from a pooled analysis of 2,838 patients randomized in 7 trials , 2008 .
[13] Donald A. Berry,et al. Good Practices for Adaptive Clinical Trials in Pharmaceutical Product Development , 2009 .
[14] Kristine R Broglio,et al. Detecting an overall survival benefit that is derived from progression-free survival. , 2009, Journal of the National Cancer Institute.
[15] D. Berry,et al. I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.
[16] Diane D. Liu,et al. Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center , 2009, Clinical trials.
[17] Bradley P. Carlin,et al. Bayesian Adaptive Methods for Clinical Trials , 2010 .
[18] D. Tripathy. Adjuvant chemotherapy in Older Women with Early-Stage Breast Cancer , 2010 .
[19] D. DeMets,et al. A historical perspective on clinical trials innovation and leadership: where have the academics gone? , 2011, JAMA.
[20] J. Woodcock,et al. Development of novel combination therapies. , 2011, The New England journal of medicine.